Updated Guidelines for Use of Pneumococcal Vaccines in Adults

2023 guidelines for pneumococcal vaccination of adults aged ≥19 years

Target Group: Healthcare practitioners who provide care for adults

Sponsoring Organization: CDC's Advisory Committee on Immunization Practices (ACIP)

Background

Streptococcus pneumoniae infection is the most common bacterial cause of community-acquired pneumonia in adults. As vaccination initially reduced the prevalence of some pneumococcal strains, others replaced them, necessitating newer polyvalent vaccines. Currently, three anti-pneumococcal vaccines targeting different pneumococcal serotypes are recommended for use in adults with and without immunocompromising conditions. Two (PCV15, and PCV20) are pneumococcal conjugate vaccines and one (PPSV23) contains several pneumococcal polysaccharides.

Method: Literature review by ACIP experts on us…

Reviewing Author

Stephen G. Baum, MD

Disclosures

Consultant/Advisory BoardClinical Infectious Diseases

RoyaltiesUpToDate

Editorial BoardsMedical Letter